Baird Lowers Bright Minds Biosciences Inc. (DRUG) Price Target to $126, Maintains Outperform Rating Ahead of Upcoming TrialsFebruary 19, 2026Yahoo Finance
Baird Lowers Bright Minds Biosciences Inc. (DRUG) Price Target to $126, Maintains Outperform Rating Ahead of Upcoming TrialsFebruary 19, 2026Yahoo Finance
Baird Lowers Bright Minds Biosciences Inc. (DRUG) Price Target to $126, Maintains Outperform Rating Ahead of Upcoming TrialsFebruary 19, 2026Yahoo Finance
Baird Lowers Bright Minds Biosciences Inc. (DRUG) Price Target to $126, Maintains Outperform Rating Ahead of Upcoming TrialsFebruary 19, 2026Yahoo Finance
Baird Lowers Bright Minds Biosciences Inc. (DRUG) Price Target to $126, Maintains Outperform Rating Ahead of Upcoming TrialsFebruary 19, 2026Yahoo Finance
Jeffries Highlight Cybin D/B/A Helus Pharma (HELP)’s Science-Driven Psilocybin Therapies as Key Growth DriversFebruary 19, 2026Yahoo Finance
Jeffries Highlight Cybin D/B/A Helus Pharma (HELP)’s Science-Driven Psilocybin Therapies as Key Growth DriversFebruary 19, 2026Yahoo Finance
Jeffries Highlight Cybin D/B/A Helus Pharma (HELP)’s Science-Driven Psilocybin Therapies as Key Growth DriversFebruary 19, 2026Yahoo Finance
Jeffries Highlight Cybin D/B/A Helus Pharma (HELP)’s Science-Driven Psilocybin Therapies as Key Growth DriversFebruary 19, 2026Yahoo Finance
Jeffries Highlight Cybin D/B/A Helus Pharma (HELP)’s Science-Driven Psilocybin Therapies as Key Growth DriversFebruary 19, 2026Yahoo Finance
RBC Capital Cite GH Research PLC’s (GHRS) Long-Term Sales Potential Following Psychedelics SymposiumFebruary 19, 2026Yahoo Finance
RBC Capital Cite GH Research PLC’s (GHRS) Long-Term Sales Potential Following Psychedelics SymposiumFebruary 19, 2026Yahoo Finance
RBC Capital Cite GH Research PLC’s (GHRS) Long-Term Sales Potential Following Psychedelics SymposiumFebruary 19, 2026Yahoo Finance
RBC Capital Cite GH Research PLC’s (GHRS) Long-Term Sales Potential Following Psychedelics SymposiumFebruary 19, 2026Yahoo Finance
